Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Erythema Multiforme Reactions Following Pfizer/BioNTech (Tozinameran) Vaccination: Two Case-Reports with Positive Rechallenge and Review of the Literature

Author(s): Ons Charfi*, Ghozlane Lakhoua, Khouloud Berrim, Sarrah Kastalli, Talel Badri, Imen Aouinti, Riadh Daghfous, Ahmed Zaiem and Sihem EL Aidli

Volume 19, Issue 4, 2024

Published on: 25 July, 2023

Page: [465 - 468] Pages: 4

DOI: 10.2174/1574886318666230725101846

Price: $65

Abstract

Aim: Pfizer/BioNTech (BNT162b2) is a COVID-19 vaccine with a reassuring safety profile. The main adverse reactions are mild local reactions. Cutaneous reactions are generally minor. The most common cutaneous reaction reported was a local injection-site reaction.

Case Study: Here we present 2 cases of erythema multiform (EM) following BNT162b2 vaccination with positive rechallenge. The 1st case was about a 51-year-old woman who developed 5 days after the 1st dose of the mRNA Pfizer/BioNTech (BNT162b2) a macular, erythematous, roundshaped lesions on the hands, knees and soles. She experienced a positive rechallenge one month later.

In the 2nd case, a 55-year-old man presented 6 days following the 2nd shot of the mRNA Pfizer/ BioNTech (BNT162b2), targetoid eruption on the upper and lower members. The patient reported that he had the same skin lesions in ankles and soles few days following the 1st shot of the same vaccine.

Conclusion: Few cases of EM following COVID-19 vaccination were reported in the literature and positive rechallenge in only one case. Rechallenge was not performed in most cases.

Our two cases are particular because of the positive rechallenge in both patients. This is the gold standard to confirm that the vaccine was the culprit agent in inducing EM.

« Previous Next »
[1]
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239-45.
[http://dx.doi.org/10.1038/clpt.1981.154] [PMID: 7249508]
[2]
Frederiksen MS, Brenøe E, Trier J. Erythema multiforme minor following vaccination with paediatric vaccines. Scand J Infect Dis 2004; 36(2): 154-5.
[http://dx.doi.org/10.1080/00365540410019200] [PMID: 15061674]
[3]
Katoulis AC, Liakou A, Bozi E, et al. Erythema multiforme following vaccination for human papillomavirus. Dermatology 2010; 220(1): 60-2.
[http://dx.doi.org/10.1159/000254898] [PMID: 19887766]
[4]
Bernardini ML, D’Angelo G, Oggiano N, et al. Erythema multiforme following live attenuated trivalent measles-mumps-rubella vaccine. Acta Derm Venereol 2006; 86(4): 359-60.
[http://dx.doi.org/10.2340/00015555-0071] [PMID: 16874427]
[5]
Karatas E, Nazim A, Patel P, et al. Erythema multiforme reactions after Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccination: A case series. JAAD Case Rep 2023; 32: 55-8.
[http://dx.doi.org/10.1016/j.jdcr.2021.12.002] [PMID: 35097177]
[6]
Erythema multiforme after SARS-CoV-2 messenger RNA vaccination. QJM 2022; 115(1): 37-8.
[http://dx.doi.org/10.1093/qjmed/hcab303] [PMID: 34865149]
[7]
Buján Bonino C, Moreiras Arias N, López-Pardo Rico M, et al. Atypical erythema multiforme related to BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccine. Int J Dermatol 2021; 60(11): e466-7.
[http://dx.doi.org/10.1111/ijd.15894] [PMID: 34473839]
[8]
McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol 2021; 85(1): 46-55.
[http://dx.doi.org/10.1016/j.jaad.2021.03.092] [PMID: 33838206]
[9]
Petruzzi M, Galleggiante S, Messina S, Della Vella F. Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: A report of four cases. BMC Oral Health 2022; 22(1): 90.
[http://dx.doi.org/10.1186/s12903-022-02124-2] [PMID: 35331228]
[10]
Lavery MJ, Nawimana S, Parslew R, Stewart L. A flare of pre‐existing erythema multiforme following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccine. Clin Exp Dermatol 2021; 46(7): 1325-7.
[http://dx.doi.org/10.1111/ced.14714] [PMID: 33914926]
[11]
Katayama S, Ota M. Erythema Multiforme after BNT162b2 Vaccination. Intern Med 2022; 61(12): 1929.
[http://dx.doi.org/10.2169/internalmedicine.9544-22] [PMID: 35431308]
[12]
Wunderlich K, Dirschka T. Erythema multiforme following COVID-19 vaccination (BNT162b2). Hautarzt 2022; 73(1): 68-70.
[http://dx.doi.org/10.1007/s00105-021-04911-4] [PMID: 34676438]
[13]
Borg L, Mercieca L, Mintoff D, et al. Pfizer‐BioNTech SARS‐CoV‐2 mRNA vaccine‐associated erythema multiforme. J Eur Acad Dermatol Venereol 2022; 36(1): e22-4.
[http://dx.doi.org/10.1111/jdv.17682] [PMID: 34547125]
[14]
Kim MJ, Kim JW, Kim MS, Choi SY, Na JI. Generalized erythema multiforme‐like skin rash following the first dose of COVID‐19 vaccine (Pfizer‐BioNTech). J Eur Acad Dermatol Venereol 2022; 36(2): e98-e100.
[http://dx.doi.org/10.1111/jdv.17757] [PMID: 34661942]
[15]
Scharf C, Di Brizzi EV, Pellerone S, Liguori M, Giorgio CMR, Argenziano G. Nevocentric erythema multiforme after SARS‐COV‐2 vaccine. J Eur Acad Dermatol Venereol 2022; 36(1): e30-2.
[http://dx.doi.org/10.1111/jdv.17688] [PMID: 34547145]
[16]
Zhang L, Wang W, Li C, Chen T. Erythema multiforme after SARS‐CoV‐2 vaccine. J Eur Acad Dermatol Venereol 2022; 36(1): e32-3.
[http://dx.doi.org/10.1111/jdv.17689] [PMID: 34547118]
[17]
de las Vecillas L, López J, Morchón E, Rodriguez F, Drake M, Martino M. Viral-like reaction or hypersensitivity? erythema multiforme minor reaction and moderate eosinophilia after the Pfizer-BioNTech BNT162b2 (mRNA-Based) SARS-CoV-2 vaccine. J Investig Allergol Clin Immunol 2022; 32(1): 77-8.
[http://dx.doi.org/10.18176/jiaci.0757] [PMID: 34588156]
[18]
Iwasawa O, Kamiya K, Komine M, Ohtsuki M. Case of atypical erythema multiforme following coronavirus disease 2019 vaccination. J Dermatol 2022; 49(3): e113-4.
[http://dx.doi.org/10.1111/1346-8138.16255] [PMID: 34821413]
[19]
Saibene AM, Alliata A, Cozzi AT, et al. Erythema multiforme major following SARS‐CoV‐2 vaccine. Clin Case Rep 2021; 9(10): e04947.
[http://dx.doi.org/10.1002/ccr3.4947] [PMID: 34667612]
[20]
Lopes NT, Pinilla CEO, Gerbase AC. Erythema multiforme after CoronaVac vaccination. J Eur Acad Dermatol Venereol 2021; 35(11): e717-9.
[http://dx.doi.org/10.1111/jdv.17495] [PMID: 34236724]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy